ArticleNeuro-oncology advances

Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

Anna E M Bastiaansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.